Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
NW

NASDAQ · NWBO

Northwest Biotherapeutics, Inc.

Healthcare · Biotechnology

$0.17

Up+$0.00 (+0.49%)

Updated Nov 5, 2026, 9:08 AM

SID Score

4.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
358.21M
P/E ratio
-3.84
Dividend yield
0.00%
52-week range
— – —
Volume
4.27M
Avg. volume
3.1M

Price performance · NWBO

NWBO price history

1M range · 0 trading sessions · Daily adjusted prices

NWBO does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest NWBO news

The latest Smart Investors Daily articles mentioning NWBO.

Stock researchCompany · Overview

NWBO research

Overview

Company profile and research snapshot.

Company profile

NORTHWEST BIOTHRPUTCS INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

Northwest Biotherapeutics Announces Expansion of Its Technical Team

Northwest Biotherapeutics (OTCQB: NWBO) NWBio a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has expanded its technical team in the US. In order to balance these increased expenditures, the Company is also eliminating selected positions which are not essential for ramp-up of the Company's priority areas of operations. The net effect of these changes is a net increase in personnel headcount in the US, but with operating costs rem

Yahoo · Oct 9, 2026

Northwest Biotherapeutics Announces NHSBT Collaboration to Support DCVax-L Production in the UK

Northwest Biotherapeutics (USOTC:NWBO) has entered into a collaboration with NHS Blood and Transplant to support manufacturing of its experimental DCVax-L cancer vaccine, strengthening UK production infrastructure while the treatment’s marketing authorisation application remains under regulatory review. Key Investor TakeawaysNorthwest Biotherapeutics (USOTC:NWBO) has established an NHSBT collaboration to support the production of its personalised DCVax-L immunotherapy.

Yahoo · Oct 8, 2026

Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production

Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, and the UK National Health Service Blood and Transplant ("NHSBT") announce that they have entered into a collaboration, as the culmination of months of joint efforts by the parties, to support production of the Company's experimental cancer vaccine DCVax®-L.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By